Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
VNDA Vanda Pharmaceuticals Inc. daily Stock Chart
VNDA [NASD]
Vanda Pharmaceuticals Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E5.52 EPS (ttm)2.14 Insider Own3.90% Shs Outstand53.81M Perf Week2.43%
Market Cap649.79M Forward P/E787.33 EPS next Y0.02 Insider Trans-3.50% Shs Float52.79M Perf Month10.68%
Income116.70M PEG- EPS next Q0.04 Inst Own98.00% Short Float11.80% Perf Quarter4.51%
Sales237.50M P/S2.74 EPS this Y343.30% Inst Trans-0.24% Short Ratio8.88 Perf Half Y-21.99%
Book/sh7.74 P/B1.53 EPS next Y-93.59% ROA25.60% Target Price17.00 Perf Year-12.97%
Cash/sh5.68 P/C2.08 EPS next 5Y- ROE30.60% 52W Range7.12 - 17.85 Perf YTD-28.03%
Dividend- P/FCF18.89 EPS past 5Y30.80% ROI26.60% 52W High-33.84% Beta0.54
Dividend %- Quick Ratio6.10 Sales past 5Y35.30% Gross Margin89.60% 52W Low65.87% ATR0.56
Employees284 Current Ratio6.10 Sales Q/Q21.60% Oper. Margin10.40% RSI (14)55.22 Volatility4.81% 5.12%
OptionableYes Debt/Eq0.00 EPS Q/Q176.40% Profit Margin49.10% Rel Volume1.03 Prev Close11.36
ShortableYes LT Debt/Eq0.00 EarningsMay 06 AMC Payout0.00% Avg Volume701.60K Price11.81
Recom2.20 SMA202.60% SMA503.42% SMA200-8.55% Volume719,466 Change3.96%
Jun-09-20Downgrade Citigroup Buy → Neutral $14
Mar-16-20Downgrade Oppenheimer Perform → Underperform
Mar-12-20Upgrade Citigroup Neutral → Buy $14
Nov-07-19Downgrade Citigroup Buy → Neutral $19
Aug-01-19Upgrade Citigroup Neutral → Buy $19
Jul-25-19Downgrade Stifel Buy → Hold $26 → $17
Dec-11-18Downgrade Oppenheimer Outperform → Perform
Dec-04-18Upgrade Cantor Fitzgerald Neutral → Overweight
Dec-04-18Reiterated Jefferies Buy $30 → $40
Nov-08-18Resumed Jefferies Buy
Sep-21-18Resumed Oppenheimer Outperform
May-23-18Initiated Citigroup Buy $26
Jan-19-18Initiated Seaport Global Securities Buy $20
Sep-14-17Reiterated Piper Jaffray Overweight $23 → $26
Jun-27-17Resumed Piper Jaffray Overweight $23
May-26-17Initiated H.C. Wainwright Buy $18
Apr-12-17Initiated Oppenheimer Outperform $21
Nov-09-16Initiated Aegis Capital Buy $24
Oct-06-16Resumed Jefferies Buy
Jan-09-15Initiated Canaccord Genuity Buy $22
Jul-14-20 11:02AM  
FDA Grants Extra Access to Vanda's Tradipitant to a Patient
Zacks
08:04AM  
The Daily Biotech Pulse: Blueprint, Roche Ink $1.7B Cancer Drug Collaboration, INmune's Positive Alzheimer's Readout, Edwards, Abbott Settle Patent Lawsuits
Benzinga
Jul-13-20 04:30PM  
FDA grants authorization for Individual Patient Expanded Access Protocol for the use of tradipitant for gastroparesis
PR Newswire
Jun-19-20 02:38PM  
Vanda Pharmaceuticals Inc. (VNDA): Hedge Funds Sticking Around
Insider Monkey
Jun-09-20 02:09PM  
Top Biotech Stocks for Q3 2020
Investopedia
May-26-20 07:00AM  
Vanda Pharmaceuticals Announces Virtual 2020 Stockholder Meeting
PR Newswire
May-21-20 05:08PM  
U.S. doctors call for remdesivir data to guide coronavirus treatment
Reuters
May-20-20 05:20PM  
Vanda Pharmaceuticals Wins Motion To Dismiss False Claims Act Lawsuit
PR Newswire +6.73%
10:45AM  
Vanda Pharmaceuticals CEO's Proposal on Clinical Trial Data Sharing, COVID-19 and Remdesivir
PR Newswire
May-15-20 11:43AM  
1 Pharma Stock to Avoid at All Costs
Motley Fool
May-14-20 07:03AM  
This Under-the-Radar Drug Developer May Have an Answer for Patients With Severe COVID-19
Motley Fool
May-13-20 07:00AM  
Vanda Pharmaceuticals Announces Agreement with FDA on Resubmission of the Application for HETLIOZ® for the Treatment of Patients with Smith-Magenis Syndrome
PR Newswire
May-08-20 07:32PM  
Edited Transcript of VNDA earnings conference call or presentation 6-May-20 8:30pm GMT
Thomson Reuters StreetEvents
May-07-20 11:31AM  
Vanda Pharmaceuticals (VNDA) Q1 2020 Earnings Call Transcript
Motley Fool
May-06-20 06:45PM  
Vanda Pharmaceuticals (VNDA) Meets Q1 Earnings Estimates
Zacks
Apr-29-20 04:05PM  
Vanda Pharmaceuticals to Announce First Quarter 2020 Financial Results on May 6, 2020
PR Newswire
12:34PM  
Analysts Estimate Vanda Pharmaceuticals (VNDA) to Report a Decline in Earnings: What to Look Out for
Zacks
Apr-27-20 02:18PM  
What Is Vanda Pharmaceuticals's (NASDAQ:VNDA) P/E Ratio After Its Share Price Rocketed?
Simply Wall St.
Apr-23-20 09:12AM  
Another 140,000 apply for unemployment benefits in D.C., Md. and Va.
American City Business Journals
Apr-22-20 01:01PM  
Is Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) CEO Paid At A Competitive Rate?
Simply Wall St.
Apr-21-20 05:14PM  
This company gets FDA green light to proceed with study on possible COVID-19 treatment
Yahoo Finance Video
Apr-17-20 10:00AM  
Company News for Apr 17, 2020
Zacks
08:54AM  
Northam requests more federal aid, Montgomery County steps up PPE funding
American City Business Journals
Apr-16-20 10:58AM  
Vanda Begins Enrollment in Study for Severe Coronavirus Infection
Zacks +6.91%
08:09AM  
The Daily Biotech Pulse: FDA Nod For UroGen, Novavax Coronavirus Vaccine To Enter Clinics, Soligenix Licenses Vaccine Adjuvant
Benzinga
Apr-15-20 04:15PM  
Vanda Pharmaceuticals Announces Initiation of "CALYPSO" to Study the Role of Genetic Variation in COVID-19 Infections in Collaboration With University of Washington Medicine
PR Newswire -7.79%
04:05PM  
Vanda Pharmaceuticals, Northwell Health Conduct ODYSSEY Trial In Patients With Severe COVID-19 Pneumonia
PR Newswire
Apr-09-20 07:52AM  
The Daily Biotech Pulse: FDA Nod For Pfizer, Vanda Forges Partnership For COVID-19 Drug Research, Neuronetics Pre-Announces Revenue Shortfall
Benzinga
Apr-08-20 04:05PM  
Vanda Pharmaceuticals Inc. And The University of Illinois at Chicago Announce Partnership To Identify Novel Antivirals Against COVID-19
PR Newswire
Apr-03-20 02:26PM  
These D.C.-area biotech companies are making progress on COVID-19. Heres the latest.
American City Business Journals -6.81%
Apr-02-20 01:36PM  
Vanda Pharmaceuticals Announces the Initiation of ODYSSEY, an FDA Approved Clinical Study of Tradipitant in Hospitalized Patients with Severe COVID-19 Pneumonia
PR Newswire +14.08%
Mar-19-20 12:59PM  
Vanda Pharmaceuticals hits another snag with FDA
American City Business Journals +9.47%
Mar-10-20 05:13PM  
Edited Transcript of VNDA earnings conference call or presentation 25-Feb-20 9:30pm GMT
Thomson Reuters StreetEvents +8.69%
Feb-27-20 05:35PM  
Vanda Pharmaceuticals Announces Participation at March 2020 Investor Conferences
PR Newswire
Feb-26-20 03:05PM  
Vandas latest study failed. But revenue grew in 2019.
American City Business Journals
Feb-25-20 04:13PM  
Vanda Reports results from the EPIONE study of Tradipitant in the treatment of Pruritus in Atopic Dermatitis
PR Newswire
04:01PM  
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
PR Newswire
Feb-21-20 12:26PM  
Should We Be Delighted With Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) ROE Of 30%?
Simply Wall St. -9.13%
Feb-19-20 07:00AM  
Vanda Pharmaceuticals Appoints Stephen Ray Mitchell to Board of Directors
PR Newswire
Feb-18-20 08:22PM  
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results on February 25, 2020
PR Newswire +5.28%
Feb-05-20 09:15AM  
Vertex (VRTX) Hits 52-Week High, Can the Run Continue?
Zacks
Feb-03-20 03:28PM  
Court rules against Vanda, in favor of FDA on clinical trials suit
American City Business Journals
Jan-31-20 06:24PM  
Vanda Pharmaceuticals Comments on Court Ruling
PR Newswire
Jan-16-20 02:57PM  
Vandas patent challenge over its schizophrenia drug is finally over. But it's not their only generics threat.
American City Business Journals
Jan-13-20 02:11PM  
Vanda Pharmaceuticals Wins Key U.S. Supreme Court Patent Ruling on Fanapt®
PR Newswire -5.61%
Jan-12-20 03:34PM  
3 Small Caps to Consider for Growth
GuruFocus.com
Dec-29-19 09:40PM  
Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus
Benzinga
Dec-23-19 02:27PM  
Do Vanda Pharmaceuticals's (NASDAQ:VNDA) Earnings Warrant Your Attention?
Simply Wall St.
Dec-12-19 05:15PM  
Mihael H. Polymeropoulos, MD, President and CEO of Vanda Pharmaceuticals Inc., to Receive The Physicians Committee for Responsible Medicine Trailblazer Award
PR Newswire
Dec-10-19 09:12PM  
Vanda Pharmaceuticals Inc. (VNDA): Hedge Funds In Wait-and-See Mode
Insider Monkey
Nov-19-19 07:15AM  
Edited Transcript of VNDA earnings conference call or presentation 6-Nov-19 9:30pm GMT
Thomson Reuters StreetEvents
Nov-18-19 04:01PM  
Vanda Pharmaceuticals Announces Participation at November 2019 Investor Conferences
PR Newswire
10:04AM  
These Stocks Could Bounce High in January and Beyond
GuruFocus.com
Nov-14-19 10:35AM  
Top Ranked Value Stocks to Buy for November 14th
Zacks
Nov-07-19 07:18AM  
The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs
Benzinga +10.58%
Nov-06-19 04:01PM  
Vanda Pharmaceuticals Reports Third Quarter 2019 Financial Results
PR Newswire
Oct-31-19 01:25PM  
Hedge Funds Have Never Been Less Bullish On Vanda Pharmaceuticals Inc. (VNDA)
Insider Monkey
Oct-30-19 04:30PM  
Vanda Pharmaceuticals to Announce Third Quarter 2019 Financial Results on November 6, 2019
PR Newswire
10:33AM  
Analysts Estimate Vanda Pharmaceuticals (VNDA) to Report a Decline in Earnings: What to Look Out for
Zacks
Oct-28-19 04:30PM  
Vanda Pharmaceuticals Appoints Anne Sempowski Ward to Board of Directors
PR Newswire
Oct-23-19 04:01PM  
Vanda Announces New Study Results Showing a High Degree of Inbreeding in Beagle Dogs
PR Newswire
Oct-16-19 04:01PM  
Vanda Applauds White House Issuance of Executive Orders Requiring Federal Agencies to be Transparent in Policymaking and Enforcement
PR Newswire
Oct-15-19 08:25AM  
SHAREHOLDER ALERT: The Law Offices of Timothy L. Miles Announces that Vanda Pharmaceuticals Inc. (VNDA) Sued for Misleading Investors; Shareholders Urged to Contact the Firm
ACCESSWIRE
Oct-10-19 01:49PM  
Volatility 101: Should Vanda Pharmaceuticals (NASDAQ:VNDA) Shares Have Dropped 42%?
Simply Wall St.
Sep-25-19 06:18PM  
Menlo (MNLO) Completes Enrollment in Phase II Pruritus Study
Zacks +5.53%
Sep-11-19 05:20PM  
Vanda Pharmaceuticals Applauds the EPA's Landmark Commitment to Eliminate Animal Testing and Urges the Food and Drug Administration to End Unnecessary and Scientifically Flawed Animal Toxicity Studies
PR Newswire
Sep-04-19 10:55AM  
Here's What We Think About Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) CEO Pay
Simply Wall St.
Aug-28-19 08:02AM  
Attention Biotech Investors: Mark Your Calendar For These September PDUFA Dates
Benzinga
Aug-21-19 11:00AM  
Biotech Stock Roundup: CELG's Inrebic Gets FDA Nod, SRPT Suffers Setback & More
Zacks
07:00AM  
Vanda Pharmaceuticals Announces the Appointments of a Chief Corporate Affairs and Communications Officer and a Chief Marketing Officer
PR Newswire
Aug-20-19 08:34AM  
Vanda Receives CRL From FDA for sNDA of Jet Lag Treatment
Zacks
Aug-19-19 02:54PM  
FDA rejects Vandas drug application for jet lag disorder
American City Business Journals
10:06AM  
FDA Issues Complete Response For Vanda's Hetlioz In Jet Lag Disorder
Benzinga
07:00AM  
Vanda Pharmaceuticals FDA Update for HETLIOZ® in the Treatment of Jet Lag Disorder
PR Newswire
Aug-13-19 03:23PM  
Biotech Stock On The Radar: Is Vanda A Buy Ahead Of Its PDUFA Date?
Benzinga
Aug-11-19 03:46PM  
The Week Ahead In Biotech: Vanda Awaits FDA Decision, BioVie Plans IPO
Benzinga
Aug-09-19 01:35PM  
Edited Transcript of VNDA earnings conference call or presentation 31-Jul-19 8:30pm GMT
Thomson Reuters StreetEvents
Aug-08-19 10:20AM  
Why Vanda (VNDA) Might be Well Poised for a Surge
Zacks
Aug-05-19 03:59PM  
Vanda Pharmaceuticals Returns to Profitability in Q2
Motley Fool
02:54PM  
Should You Be Worried About Insider Transactions At Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)?
Simply Wall St.
Aug-02-19 02:45PM  
This D.C. biotech has hit some bumps this year. Its also breaking revenue records.
American City Business Journals
Aug-01-19 05:36PM  
Here's Why Vanda Pharmaceuticals Stock Soared on Thursday
Motley Fool +26.83%
04:13PM  
This Medtech's CEO Promised To 'Correct The Course' That Didn't Happen
Investor's Business Daily
11:03AM  
This Medtech's CEO Promised To 'Correct The Course' That Didn't Happen
Investor's Business Daily
05:24AM  
Vanda Pharmaceuticals (VNDA) Q2 2019 Earnings Call Transcript
Motley Fool
Jul-31-19 06:35PM  
Vanda Pharmaceuticals (VNDA) Surpasses Q2 Earnings and Revenue Estimates
Zacks
04:01PM  
Vanda Pharmaceuticals Reports Second Quarter 2019 Financial Results
PR Newswire
Jul-29-19 02:19PM  
Shareholder Alert: Robbins Arroyo LLP: Vanda Pharmaceuticals Inc. (VNDA) Sued for Misleading Investors
Business Wire
Jul-24-19 10:33AM  
Analysts Estimate Vanda Pharmaceuticals (VNDA) to Report a Decline in Earnings: What to Look Out for
Zacks
Jul-23-19 07:26AM  
The Daily Biotech Pulse: Acadia Schizophrenia Drug Fails, Viveve Plummets, Eisai Gets Breakthrough Therapy Designation
Benzinga
Jul-22-19 04:01PM  
Vanda Pharmaceuticals to Announce Second Quarter 2019 Financial Results on July 31, 2019
PR Newswire
03:02PM  
FDA points to deficiencies in Vanda's latest drug application
American City Business Journals
07:00AM  
Vanda Pharmaceuticals FDA Update for HETLIOZ® in the Treatment of Jet Lag Disorder
PR Newswire
Jul-18-19 02:09PM  
How Do You Test a New Seasickness Drug? Take Pill, Set Sail
Bloomberg
Jul-17-19 03:00PM  
Nausea no more? D.C. biotech gets motion sickness drug to next stage.
American City Business Journals
Jul-16-19 04:15PM  
Tradipitant Effective in Preventing Motion Sickness
PR Newswire
03:35PM  
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Vanda Pharmaceuticals Inc. VNDA
GlobeNewswire
Jul-08-19 10:16AM  
Is Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Potentially Underrated?
Simply Wall St.
Jun-19-19 09:32PM  
Is Vanda Pharmaceuticals Inc. (VNDA) A Good Stock To Buy?
Insider Monkey
Jun-18-19 09:50AM  
Vanda Pharmaceuticals to Present at the JMP Securities Life Sciences Conference
PR Newswire
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; and a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as for the treatment of secretory diarrhea disorders, including cholera. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Watkins ThomasDirectorMay 29Option Exercise7.3815,000110,70045,000Jun 02 04:13 PM
Watkins ThomasDirectorMay 29Sale11.509,677111,28635,323Jun 02 04:13 PM
DUGAN RICHARD WDirectorMay 28Option Exercise7.3815,000110,70050,770May 29 04:10 PM
DUGAN RICHARD WDirectorMay 28Sale11.0410,129111,80640,641May 29 04:10 PM
Williams TimothySVP & General CounselMar 03Sale10.511,23713,00483,040Mar 04 05:03 PM
Kelly James PatrickEVP & Chief Financial OfficerMar 03Sale10.765,88963,359186,869Mar 04 05:01 PM
Birznieks GuntherSVP, Business DevelopmentMar 03Sale10.665,53558,984159,473Mar 04 05:00 PM
Polymeropoulos Mihael HristosPresident and CEOMar 03Sale10.985,15256,5441,278,999Mar 04 05:02 PM
Polymeropoulos Mihael HristosPresident and CEOMar 02Sale10.5710,428110,2111,284,151Mar 04 05:02 PM
Birznieks GuntherSVP, Business DevelopmentMar 02Sale10.0412,223122,686165,008Mar 04 05:00 PM
Kelly James PatrickEVP & Chief Financial OfficerMar 02Sale10.1912,968132,087192,758Mar 04 05:01 PM
Reverberi Gian PieroSVP & Chief Commercial OfficerMar 02Sale10.181,45014,755165,384Mar 04 05:02 PM
Williams TimothySVP & General CounselMar 02Sale10.303,14832,43684,277Mar 04 05:03 PM
Polymeropoulos Mihael HristosPresident and CEOJan 02Sale16.009,467151,4931,234,579Jan 06 05:26 PM
Reverberi Gian PieroSVP & Chief Commercial OfficerJan 02Sale16.061,15518,551166,834Jan 06 05:26 PM
Kelly James PatrickEVP & Chief Financial OfficerJan 02Sale15.944,02064,086205,726Jan 06 05:25 PM
Birznieks GuntherSVP, Business DevelopmentJan 02Sale15.934,02064,021147,231Jan 06 05:25 PM
Polymeropoulos Mihael HristosPresident and CEODec 12Option Exercise10.6585,801913,7811,314,082Dec 13 04:21 PM
Polymeropoulos Mihael HristosPresident and CEODec 12Sale16.9870,0361,189,3511,244,046Dec 13 04:21 PM
Polymeropoulos Mihael HristosPresident and CEODec 11Option Exercise10.6589,199949,9691,300,654Dec 13 04:21 PM
Polymeropoulos Mihael HristosPresident and CEODec 11Sale16.9272,3731,224,3771,228,281Dec 13 04:21 PM
DUGAN RICHARD WDirectorAug 26Option Exercise14.7815,000221,70050,770Aug 28 04:30 PM
DUGAN RICHARD WDirectorAug 26Sale14.8515,000222,75035,770Aug 28 04:30 PM
Williams TimothySVP & General CounselAug 14Sale14.692,57537,82957,425Aug 15 04:58 PM
open in yahoo | open in reuters | open in google